Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Strong Trading Volume – Here’s What Happened

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY) saw unusually-strong trading volume on Friday. 1,327,216 shares traded hands during mid-day trading, an increase of 799% from the previous session’s volume of 147,664 shares. The stock last traded at $12.4170 and had previously closed at $12.45.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Down 0.0%

The company has a market cap of $28.04 billion, a price-to-earnings ratio of 15.75 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a 50-day moving average price of $13.18 and a 200 day moving average price of $12.40.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. The firm had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Sell-side analysts predict that Fresenius SE & Co. will post 1.08 EPS for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.